Term
| most common non-small cell lung cancer |
|
Definition
| adenocarcinoma (most are peripheral in origin) |
|
|
Term
| second most common non-small cell lung cancer |
|
Definition
| squamous: linked to smoking history, centrally located near a bronchus |
|
|
Term
| grows and spread quickly, poor prognosis (NSCLC) |
|
Definition
|
|
Term
| highly emetogenic, ototoxic, renal toxic |
|
Definition
|
|
Term
| highly emetogenic, renal toxic--uses calvert formula for dosing |
|
Definition
|
|
Term
| developed specifically for cisplatin to help pts tolerate it |
|
Definition
|
|
Term
| platinum agent not used in lung cancer, mostly in colon |
|
Definition
|
|
Term
| cause anemia, neutropenia, thrombocytopenia |
|
Definition
|
|
Term
| Comes from pacific eu tree, can be neurotoxic, moderate to low emetogenic potential |
|
Definition
|
|
Term
| better tolerated,comes from needles of European Euu Tree |
|
Definition
|
|
Term
| Mildly emetogenic, severe hypotension, with rapid infusion |
|
Definition
|
|
Term
| Neurotoxic, vinca alkaloid-- fatal if administered intrathecally |
|
Definition
|
|
Term
| same precautions as vinblastine |
|
Definition
|
|
Term
| many drug interactions CYP3A4 metabolized, rashes, nost associated w/ typical chemo side effects, oral but very expensive |
|
Definition
| Tyrosine kinase inhibitors |
|
|
Term
| improve OS by 3.3 months, second or third line (also used for pancreatic cancer) |
|
Definition
|
|
Term
| used to treat NSCLC that is advanced or metastasis and is caused by a defect in gene called ALK |
|
Definition
|
|
Term
| prolongs survival, improves symptom control, and yields superior quality of life compared to best supportive care (NSCLC) |
|
Definition
| Platinum based chemotherapy |
|
|
Term
| 1st line therapy in advanced disease guidelines (NSCLC) |
|
Definition
| Bevaczimuab + chemo or chemo along indicated in PS 0-2 w/ advanced or recurrent NSCLC |
|
|
Term
| 2nd line therapy in pts who have experienced dx progression either during or after 1st line therapy (NSCLC) |
|
Definition
| docetaxel or pemetrexed, or tyrosin kinase inhibitor: Erlotinib |
|
|
Term
|
Definition
| Erlotinib has proven statistically superior to BSC with respect to survival |
|
|
